Andreas Maetzel Person-Info 

( Ich bin Andreas Maetzel)

News

KVD900, Investigational Therapy for HAE, Fares Well in Phase 1 Trial

angioedemanews.com
Read about promising data from a Phase 1 trial showing that KalVista's KVD900 rapidly reduced the activity of plasma kallikrein in HAE patients.
Dossier exportieren
+1